

Sanofi expands collaboration with Translate Bio to develop mRNA COVID-19 vaccine

March 27, 2020



Forward looking statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, the impact of global disruptions, including pandemics, cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2019. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements

Agenda

COVID-19 response

mRNA technology

Q&A

David Loew EVP Vaccines, Sanofi Pasteur



Ronald Renaud, Jr CEO, Translate Bio



John Shiver SVP R&D, Sanofi Pasteur



A unique portfolio to fight the public health emergency

Sanofi's multi-pronged approach to combat COVID-19⁽¹⁾

1

Vaccines

BARDA collaboration: Recombinant DNA vaccine

 **Translate**BIO mRNA vaccine

2

Antibody


Anti IL-6⁽²⁾

KEVZARA
(sarilumab)

3


Small molecule

hydroxychloroquine
(Plaquenil®)




Sanofi adding a second vaccine approach for COVID-19

1 – Baculovirus recombinant vaccine approach




2 – Translate Bio mRNA vaccine approach



Sanofi to capitalize on benefits of mRNA vaccines platform

Existing agreement to develop mRNA vaccines for five infectious diseases

Rodent and non-human primate studies complete on other vaccine programs



Lead mRNA and LNP candidates tested across disease targets

Large scale process development in progress for lead mRNA constructs

Opportunity to scale-up to commercial volumes

Attractive expansion of existing collaboration agreement



Progress

- Encouraging preclinical data across multiple infectious disease targets
- COVID-19 now added to the 5 vaccines of original agreement from 2018
- Opportunity to accelerate development of mRNA vaccine platform

Terms

- No upfront fee for addition of COVID-19 license due to pandemic
- Pandemic COVID-19 – no milestone payments; royalties to be negotiated⁽¹⁾
- Exploring public-private partnership for funding of development program

Q&A session



David Loew
EVP, Sanofi Pasteur



Ronald Renaud, Jr
CEO, Translate Bio



John Shiver
SVP R&D, Sanofi Pasteur